CORE LAB REPORTS THIRD QUARTER 2024 RESULTS
Core Laboratories (NYSE: CLB) reported strong Q3 2024 results with revenue of $134.4 million, up 3% sequentially and 7% year-over-year. Operating income reached $19.8 million, with operating margins ex-items of 14%, up 100 basis points sequentially. The company achieved $0.25 EPS and generated $10.4 million in free cash flow. Net debt was reduced by $11.8 million, bringing the debt leverage ratio to 1.47. Reservoir Description revenue grew to $88.8 million, while Production Enhancement posted $45.6 million. The company continues to expand internationally and in Carbon Capture and Sequestration projects, despite some headwinds from geopolitical conflicts and weather-related delays.
Core Laboratories (NYSE: CLB) ha riportato risultati solidi per il terzo trimestre del 2024, con un fatturato di 134,4 milioni di dollari, in aumento del 3% rispetto al trimestre precedente e del 7% rispetto all'anno precedente. Il reddito operativo ha raggiunto 19,8 milioni di dollari, con margini operativi esclusi i costi straordinari del 14%, in aumento di 100 punti base rispetto al trimestre precedente. L'azienda ha ottenuto un utile per azione di 0,25 dollari e ha generato 10,4 milioni di dollari di flusso di cassa libero. Il debito netto è stato ridotto di 11,8 milioni di dollari, portando il rapporto di indebitamento a 1,47. I ricavi per la Descrizione dei Serbatoi sono cresciuti a 88,8 milioni di dollari, mentre il miglioramento della produzione ha registrato 45,6 milioni di dollari. L'azienda continua a espandersi a livello internazionale e nei progetti di cattura e stoccaggio di carbonio, nonostante alcune difficoltà dovute a conflitti geopolitici e ritardi legati alle condizioni atmosferiche.
Core Laboratories (NYSE: CLB) informó resultados sólidos para el tercer trimestre de 2024, con ingresos de 134,4 millones de dólares, un aumento del 3% secuencialmente y del 7% interanual. El ingreso operativo alcanzó 19,8 millones de dólares, con márgenes operativos excluyendo ítems del 14%, lo que representa un aumento de 100 puntos base secuencialmente. La compañía logró un EPS de 0,25 dólares y generó 10,4 millones de dólares en flujo de caja libre. La deuda neta se redujo en 11,8 millones de dólares, llevando la relación de apalancamiento a 1,47. Los ingresos de Descripción de Reservorios crecieron a 88,8 millones de dólares, mientras que Mejora de Producción reportó 45,6 millones de dólares. La compañía continúa expandiéndose internacionalmente y en proyectos de Captura y Secuestro de Carbono, a pesar de algunos vientos en contra debido a conflictos geopolíticos y retrasos relacionados con el clima.
Core Laboratories (NYSE: CLB)는 2024년 3분기 실적을 발표하며 1억 3,440만 달러의 매출을 기록했으며, 이는 전 분기 대비 3% 및 전년 대비 7% 증가한 수치입니다. 운영 수익은 1,980만 달러에 달했으며, 항목 제외 운영 마진은 14%로 전 분기 대비 100bp 증가했습니다. 회사는 주당 0.25 달러의 EPS를 달성했으며, 1,040만 달러의 자유 현금 흐름을 생성했습니다. 순부채는 1,180만 달러 감소하여 부채 비율이 1.47로 조정되었습니다. 저수지 서술 부문의 매출은 8,880만 달러로 증가했으며, 생산 개선 부문은 4,560만 달러를 기록했습니다. 회사는 국제적으로 및 탄소 포집과 저장 프로젝트에서 계속 확장하고 있으며, 지정학적 갈등 및 날씨와 관련된 지연이 있음에도 불구하고 성장하고 있습니다.
Core Laboratories (NYSE: CLB) a annoncé de solides résultats pour le troisième trimestre 2024, avec des revenus de 134,4 millions de dollars, en hausse de 3 % par rapport au trimestre précédent et de 7 % par rapport à l'année précédente. Le résultat d'exploitation a atteint 19,8 millions de dollars, avec des marges d'exploitation hors éléments de 14 %, en hausse de 100 points de base par rapport au trimestre précédent. L'entreprise a réalisé un BPA de 0,25 dollar et a généré 10,4 millions de dollars de flux de trésorerie libre. La dette nette a été réduite de 11,8 millions de dollars, faisant passer le ratio d'endettement à 1,47. Les revenus de la description des réservoirs ont augmenté pour atteindre 88,8 millions de dollars, tandis que l'amélioration de la production a enregistré 45,6 millions de dollars. L'entreprise continue de s'étendre à l'international et dans des projets de capture et de stockage du carbone, malgré quelques obstacles dus à des conflits géopolitiques et des retards liés aux conditions météorologiques.
Core Laboratories (NYSE: CLB) berichtete über starke Ergebnisse im 3. Quartal 2024 mit einem Umsatz von 134,4 Millionen Dollar, was einem Anstieg von 3 % im Vergleich zum vorangegangenen Quartal und von 7 % im Jahresvergleich entspricht. Das Betriebsgewinn erreichte 19,8 Millionen Dollar, mit operativen Margen ohne Sondereffekte von 14 %, was einem Anstieg um 100 Basispunkte gegenüber dem vorherigen Quartal entspricht. Das Unternehmen erzielte ein EPS von 0,25 Dollar und generierte 10,4 Millionen Dollar an freiem Cashflow. Die Nettoverschuldung wurde um 11,8 Millionen Dollar reduziert, was das Verschuldungsratio auf 1,47 senkt. Die Einnahmen aus Reservoir-Beschreibung stiegen auf 88,8 Millionen Dollar, während die Produktionssteigerung 45,6 Millionen Dollar einbrachte. Das Unternehmen expandiert weiterhin international und in Projekten zur Kohlenstoffabscheidung und -speicherung, trotz einiger Herausforderungen durch geopolitische Konflikte und wetterbedingte Verzögerungen.
- Revenue increased 7% year-over-year to $134.4 million
- Operating income ex-items up 14% year-over-year to $18.2 million
- Operating margins improved by 100 basis points to 14%
- Net debt reduced by $11.8 million
- Debt leverage ratio improved to 1.47, lowest in six years
- Free cash flow of $27.1 million for first nine months of 2024
- Hurricane-related delays impacted Gulf of Mexico operations
- U.S. land activity trending lower in Q4 2024
- Projected Q4 revenue decline compared to Q3
- Lower projected Q4 EPS range of $0.20-$0.25 vs Q3's $0.25
Insights
Core Laboratories delivered a solid Q3 2024 with notable improvements across key metrics.
Two significant achievements stand out: debt reduction of
However, near-term headwinds include U.S. land activity decline, Gulf of Mexico weather disruptions and geopolitical tensions affecting international operations. The Q4 guidance suggests potential sequential decline with revenue projected at
The expansion into Carbon Capture and Sequestration (CCS) projects represents a strategic diversification that leverages Core's existing expertise while addressing growing environmental concerns. Their engagement in multiple U.S. Gulf Coast CCS evaluation contracts indicates strong market positioning in this emerging sector.
The Kuwait Oil Company contract win for offshore exploration analysis demonstrates Core's continued strength in international markets, particularly in the Middle East. Their proprietary PulverizorTM technology for plug and abandonment operations shows innovation in cost reduction and operational efficiency.
The company's outlook aligns with major energy forecasters (IEA, EIA, OPEC+) projecting crude-oil demand growth of 1.0-1.6 million barrels per day for 2025. This supports their focus on international expansion, though near-term volatility remains a concern.
- THIRD QUARTER REVENUE OF
, UP$134.4 MILLION 3% SEQUENTIALLY AND OVER7% YEAR-OVER-YEAR - THIRD QUARTER OPERATING INCOME OF
; EX-ITEMS,$19.8 MILLION , UP$18.2 MILLION 11% SEQUENTIALLY AND14% YEAR-OVER-YEAR - THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF
14% UP 100 BPS SEQUENTIALLY - THIRD QUARTER GAAP EPS OF
; EX-ITEMS,$0.25 , UP$0.25 14% SEQUENTIALLY AND YEAR-OVER-YEAR - THIRD QUARTER FREE CASH FLOW OF
$10.4 MILLION - NET DEBT REDUCED BY
; DEBT LEVERAGE RATIO REDUCED TO 1.47$11.8 MILLION - COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDEND
Core's CEO, Larry Bruno stated, "In the third quarter of 2024, Core Lab delivered solid sequential improvements in revenue, operating income, operating margins, incremental margins and earnings per share. Demand for our Reservoir Description services continued to grow across our international laboratory network despite headwinds from on-going geopolitical conflicts. In Production Enhancement, revenue increased sequentially, driven by higher international product sales. However, these improvements were somewhat offset by hurricane-related delays in diagnostic service revenue tied to suspended well operations in the Gulf of Mexico. Following positive meetings with
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately
Core Lab continues to expand its engagement in Carbon Capture and Sequestration ("CCS") projects, leveraging its expertise in reservoir characterization. In addition to Core's multi-company joint industry project that is being conducted in conjunction with Dr. Birol Dindoruk of the University of
Also, during the third quarter of 2024, engagement on projects in the
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional oil and gas reservoirs in the
In the third quarter of 2024, Core Lab's completion diagnostic technologies were utilized to provide insight into complex unconventional completions. For several years, operators in
In 2023, a national oil company in the
Liquidity, Free Cash Flow and Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the third quarter of 2024, cash from operations was
Core expects to continue generating positive free cash flow in future quarters. As of September 30, 2024, Core's net debt (defined as long-term debt less cash and cash equivalents) was
On July 24, 2024, Core's Board of Directors ("Board") announced a quarterly cash dividend of
On October 23, 2024, the Board approved a cash dividend of
Return On Invested Capital
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promotes capital efficiency and are designed to produce more predictable and superior long-term ROIC.
The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg's formula, the Company's ROIC as of September 30, 2024 was
Industry and Core Lab Outlook and Guidance
Core Lab continues to see a multi-year international recovery due to underinvestment, increasing focus on energy security and rising crude-oil demand, all supporting continued activity growth into 2025. In alignment with this outlook, Core will continue to execute its strategic plan of investing in technology and pursuing growth opportunities, while remaining well-engaged on long-cycle international projects. The IEA, EIA and OPEC+ continue to forecast growth in crude-oil demand between 1.0 and 1.6 million barrels per day for 2025, which is in addition to the natural decline of production from existing fields. As such, continued investment in the development of onshore and offshore crude-oil fields will be required to meet the projected growth in demand. In the near-term, we expect that crude-oil markets will remain volatile due to global economic and geopolitical risks and uncertainties.
Consequently, as international project activity continues to expand, committed long-term upstream projects from the
Fourth quarter 2024 guidance for both business segments includes the impact of client project delays caused by weather events in the Gulf of
Reservoir Description's fourth quarter 2024 revenue is projected to range from
The Company's fourth quarter 2024 revenue is projected to range from
The Company's fourth quarter 2024 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Fourth quarter 2024 guidance also assumes an effective tax rate of
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's third quarter 2024 earnings announcement. The call will begin at 7:30 a.m. CDT / 8:30 a.m. EDT on Thursday, October 24, 2024. To listen to the call, please go to Core's website at www.corelab.com.
Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements we make, includes forward-looking statements regarding the Company's future revenue, profitability, business strategies and developments, demand for the Company's products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the ability to achieve the benefits of the redomestication of the parent company from
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com. Connect with Core Lab on Facebook, LinkedIn and YouTube.
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||||||||||||
Three Months Ended | % Variance | |||||||||||||||
September 30, | June 30, | September 30, | vs. Q2-24 | vs. Q3-23 | ||||||||||||
REVENUE | $ | 134,397 | $ | 130,577 | $ | 125,343 | 2.9 % | 7.2 % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Costs of services and product sales | 106,805 | 102,930 | 96,617 | 3.8 % | 10.5 % | |||||||||||
General and administrative expense | 8,642 | 10,259 | 9,452 | (15.8) % | (8.6) % | |||||||||||
Depreciation and amortization | 3,676 | 3,770 | 3,929 | (2.5) % | (6.4) % | |||||||||||
Other (income) expense, net | (4,529) | (2,390) | 673 | NM | NM | |||||||||||
Total operating expenses | 114,594 | 114,569 | 110,671 | — % | 3.5 % | |||||||||||
OPERATING INCOME | 19,803 | 16,008 | 14,672 | 23.7 % | 35.0 % | |||||||||||
Interest expense | 3,108 | 3,209 | 3,147 | (3.1) % | (1.2) % | |||||||||||
Income before income taxes | 16,695 | 12,799 | 11,525 | 30.4 % | 44.9 % | |||||||||||
Income tax expense | 4,691 | 3,609 | 2,305 | 30.0 % | 103.5 % | |||||||||||
Net income | 12,004 | 9,190 | 9,220 | 30.6 % | 30.2 % | |||||||||||
Net income (loss) attributable to non-controlling interest | 259 | 158 | (37) | NM | NM | |||||||||||
Net income attributable to Core Laboratories Inc. | $ | 11,745 | $ | 9,032 | $ | 9,257 | 30.0 % | 26.9 % | ||||||||
Diluted earnings per share | $ | 0.25 | $ | 0.19 | $ | 0.19 | 31.6 % | 31.6 % | ||||||||
Diluted earnings per share attributable to Core Laboratories Inc. | $ | 0.25 | $ | 0.19 | $ | 0.19 | 31.6 % | 31.6 % | ||||||||
Diluted weighted average common shares outstanding | 47,820 | 47,743 | 47,604 | 0.2 % | 0.5 % | |||||||||||
Effective tax rate | 28 | % | 28 | % | 20 | % | NM | NM | ||||||||
SEGMENT INFORMATION: | ||||||||||||||||
Revenue: | ||||||||||||||||
Reservoir Description | $ | 88,840 | $ | 86,277 | $ | 85,145 | 3.0 % | 4.3 % | ||||||||
Production Enhancement | 45,557 | 44,300 | 40,198 | 2.8 % | 13.3 % | |||||||||||
Consolidated | $ | 134,397 | $ | 130,577 | $ | 125,343 | 2.9 % | 7.2 % | ||||||||
Operating income: | ||||||||||||||||
Reservoir Description | $ | 16,487 | $ | 11,443 | $ | 12,992 | 44.1 % | 26.9 % | ||||||||
Production Enhancement | 3,232 | 4,401 | 1,544 | (26.6) % | 109.3 % | |||||||||||
Corporate and Other | 84 | 164 | 136 | NM | NM | |||||||||||
Consolidated | $ | 19,803 | $ | 16,008 | $ | 14,672 | 23.7 % | 35.0 % | ||||||||
"NM" means not meaningful |
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||||||
Nine Months Ended | % Variance | |||||||||
2024 | 2023 | |||||||||
REVENUE | $ | 394,611 | $ | 381,580 | 3.4 % | |||||
OPERATING EXPENSES: | ||||||||||
Costs of services and product sales | 314,323 | 298,440 | 5.3 % | |||||||
General and administrative expense | 30,690 | 31,594 | (2.9) % | |||||||
Depreciation and amortization | 11,289 | 11,910 | (5.2) % | |||||||
Other (income) expense, net | (6,073) | (423) | NM | |||||||
Total operating expenses | 350,229 | 341,521 | 2.5 % | |||||||
OPERATING INCOME | 44,382 | 40,059 | 10.8 % | |||||||
Interest expense | 9,740 | 9,812 | (0.7) % | |||||||
Income before income taxes | 34,642 | 30,247 | 14.5 % | |||||||
Income tax expense (benefit) | 9,958 | (4,344) | NM | |||||||
Net income | 24,684 | 34,591 | (28.6) % | |||||||
Net income attributable to non-controlling interest | 687 | 115 | NM | |||||||
Net income attributable to Core Laboratories Inc. | $ | 23,997 | $ | 34,476 | (30.4) % | |||||
Diluted earnings per share | $ | 0.52 | $ | 0.73 | (28.8) % | |||||
Diluted earnings per share attributable to Core Laboratories Inc. | $ | 0.50 | $ | 0.73 | (31.5) % | |||||
Diluted weighted average common shares outstanding | 47,690 | 47,536 | 0.3 % | |||||||
Effective tax rate | 29 | % | (14) | % | NM | |||||
SEGMENT INFORMATION: | ||||||||||
Revenue: | ||||||||||
Reservoir Description | $ | 259,353 | $ | 248,717 | 4.3 % | |||||
Production Enhancement | 135,258 | 132,863 | 1.8 % | |||||||
Consolidated | $ | 394,611 | $ | 381,580 | 3.4 % | |||||
Operating income: | ||||||||||
Reservoir Description | $ | 34,823 | $ | 28,780 | 21.0 % | |||||
Production Enhancement | 9,209 | 10,324 | (10.8) % | |||||||
Corporate and Other | 350 | 955 | NM | |||||||
Consolidated | $ | 44,382 | $ | 40,059 | 10.8 % | |||||
"NM" means not meaningful |
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) | ||||||||||||||||
% Variance | ||||||||||||||||
ASSETS: | September 30, | June 30, | December 31, | vs. Q2-24 | vs. Q4-23 | |||||||||||
Cash and cash equivalents | $ | 21,474 | $ | 17,695 | $ | 15,120 | 21.4 % | 42.0 % | ||||||||
Accounts receivable, net | 117,591 | 115,644 | 109,352 | 1.7 % | 7.5 % | |||||||||||
Inventories | 65,490 | 69,898 | 71,702 | (6.3) % | (8.7) % | |||||||||||
Other current assets | 30,672 | 30,291 | 26,962 | 1.3 % | 13.8 % | |||||||||||
Total current assets | 235,227 | 233,528 | 223,136 | 0.7 % | 5.4 % | |||||||||||
Property, plant and equipment, net | 97,606 | 98,510 | 99,626 | (0.9) % | (2.0) % | |||||||||||
Right of use assets | 56,650 | 55,689 | 53,842 | 1.7 % | 5.2 % | |||||||||||
Intangibles, goodwill and other long-term assets, net | 210,983 | 210,072 | 209,791 | 0.4 % | 0.6 % | |||||||||||
Total assets | $ | 600,466 | $ | 597,799 | $ | 586,395 | 0.4 % | 2.4 % | ||||||||
LIABILITIES AND EQUITY: | ||||||||||||||||
Accounts payable | $ | 33,627 | $ | 36,863 | $ | 33,506 | (8.8) % | 0.4 % | ||||||||
Short-term operating lease liabilities | 11,435 | 11,045 | 10,175 | 3.5 % | 12.4 % | |||||||||||
Other current liabilities | 49,876 | 49,690 | 44,416 | 0.4 % | 12.3 % | |||||||||||
Total current liabilities | 94,938 | 97,598 | 88,097 | (2.7) % | 7.8 % | |||||||||||
Long-term debt, net | 139,872 | 147,621 | 163,134 | (5.2) % | (14.3) % | |||||||||||
Long-term operating lease liabilities | 43,727 | 42,616 | 42,076 | 2.6 % | 3.9 % | |||||||||||
Other long-term liabilities | 65,508 | 64,270 | 63,281 | 1.9 % | 3.5 % | |||||||||||
Total equity | 256,421 | 245,694 | 229,807 | 4.4 % | 11.6 % | |||||||||||
Total liabilities and equity | $ | 600,466 | $ | 597,799 | $ | 586,395 | 0.4 % | 2.4 % |
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | ||||||||
Nine Months Ended September 30, | ||||||||
2024 | 2023 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net income | $ | 24,684 | $ | 34,591 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Stock-based compensation | 4,213 | 12,406 | ||||||
Depreciation and amortization | 11,289 | 11,910 | ||||||
Deferred income taxes | 102 | (14,757) | ||||||
Accounts receivable | (9,461) | 2,872 | ||||||
Inventories | 6,212 | (14,614) | ||||||
Accounts payable | (373) | (13,101) | ||||||
Other adjustments to net income | (893) | (13,947) | ||||||
Net cash provided by operating activities | 35,773 | 5,360 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Capital expenditures | (8,647) | (7,843) | ||||||
Net proceeds on life insurance policies and from insurance recovery | 4,878 | 3,375 | ||||||
Other investing activities | 934 | 262 | ||||||
Net cash used in investing activities | (2,835) | (4,206) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Repayment of long-term debt | (62,000) | (184,000) | ||||||
Proceeds from long-term debt | 38,000 | 190,000 | ||||||
Debt issuance cost | — | (1,251) | ||||||
Dividends paid | (1,407) | (1,401) | ||||||
Repurchase of common shares | (402) | (418) | ||||||
Equity related transaction costs | (756) | (2,842) | ||||||
Other financing activities | (19) | (54) | ||||||
Net cash provided by (used in) financing activities | (26,584) | 34 | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 6,354 | 1,188 | ||||||
CASH AND CASH EQUIVALENTS, beginning of period | 15,120 | 15,428 | ||||||
CASH AND CASH EQUIVALENTS, end of period | $ | 21,474 | $ | 16,616 |
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.
Reconciliation of Operating Income, Net Income and Diluted Earnings Per Share Attributable to Core Laboratories Inc. (In thousands, except per share data) (Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended | ||||||||||||
September 30, | June 30, | September 30, | ||||||||||
GAAP reported | $ | 19,803 | $ | 16,008 | $ | 14,672 | ||||||
Stock compensation (1) | (1,364) | — | — | |||||||||
Loss on lease abandonment and assets write-down (2) | — | — | 633 | |||||||||
ATM termination costs (3) | — | — | 455 | |||||||||
Foreign exchange losses (gains) | (239) | 388 | 238 | |||||||||
Excluding specific items | $ | 18,200 | $ | 16,396 | $ | 15,998 | ||||||
Net Income Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
September 30, | June 30, | September 30, | ||||||||||
GAAP reported | $ | 11,745 | $ | 9,032 | $ | 9,257 | ||||||
Stock compensation (1) | (1,091) | — | — | |||||||||
Loss on lease abandonment and assets write-down (2) | — | — | 505 | |||||||||
ATM termination costs (3) | — | — | 364 | |||||||||
Foreign exchange losses (gains) | (191) | 310 | 190 | |||||||||
Effect of higher (lower) tax rate (4) | 1,351 | 1,050 | — | |||||||||
Excluding specific items | $ | 11,814 | $ | 10,392 | $ | 10,316 | ||||||
Diluted Earnings Per Share Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
September 30, | June 30, | September 30, | ||||||||||
GAAP reported | $ | 0.25 | $ | 0.19 | $ | 0.19 | ||||||
Stock compensation (1) | (0.02) | — | — | |||||||||
Loss on lease abandonment and assets write-down (2) | — | — | 0.01 | |||||||||
ATM termination costs (3) | — | — | 0.01 | |||||||||
Foreign exchange losses (gains) | (0.01) | 0.01 | 0.01 | |||||||||
Effect of higher (lower) tax rate (4) | 0.03 | 0.02 | — | |||||||||
Excluding specific items | $ | 0.25 | $ | 0.22 | $ | 0.22 | ||||||
(1) Three months ended September 30, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share awards. |
(2) Three months ended September 30, 2023 includes the write-down of leasehold improvements, right of use assets and/or other assets and exit costs associated with consolidation of certain facilities. |
(3) Three months ended September 30, 2023 includes the write off of previously deferred costs upon termination of our "at-the-market offering" ("ATM") Program. |
(4) Three months ended September 30, 2024 and June 30, 2024 includes the effect to reflect tax expense at a normalized rate of |
Segment Information (In thousands) (Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended September 30, 2024 | ||||||||||||
Reservoir | Production | Corporate and | ||||||||||
GAAP reported | $ | 16,487 | $ | 3,232 | $ | 84 | ||||||
Stock compensation | (881) | (483) | — | |||||||||
Foreign exchange losses (gains) | (157) | (117) | 35 | |||||||||
Excluding specific items | $ | 15,449 | $ | 2,632 | $ | 119 |
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful information to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.
ROIC of
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures. Management believes that free cash flow provides useful information to investors regarding the cash available in the period that was in excess of Core's needs to fund its capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash does not represent residual cash available for distribution because Core may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow (In thousands) (Unaudited) | |||||||||
Three Months Ended | Nine Months Ended | ||||||||
September 30, 2024 | September 30, 2024 | ||||||||
Net cash provided by operating activities | $ | 13,097 | $ | 35,773 | |||||
Capital expenditures | (2,729) | (8,647) | |||||||
Free cash flow | $ | 10,368 | $ | 27,126 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-third-quarter-2024-results-302285122.html
SOURCE Core Laboratories Inc
FAQ
What was Core Laboratories (CLB) revenue in Q3 2024?
What was Core Laboratories (CLB) EPS for Q3 2024?
What is Core Laboratories (CLB) Q4 2024 guidance?